Windtree Therapeutics Inc - Asset Resilience Ratio
Windtree Therapeutics Inc (WINT) has an Asset Resilience Ratio of 0.00% as of December 2019. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See WINT working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1996–2019)
This chart shows how Windtree Therapeutics Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Windtree Therapeutics Inc assets under control.
Liquid Assets Composition Over Time
This chart breaks down Windtree Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read WINT liabilities breakdown for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Windtree Therapeutics Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Windtree Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Windtree Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for Windtree Therapeutics Inc (1996–2019)
The table below shows the annual Asset Resilience Ratio data for Windtree Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2019-12-31 | 0.00% | $0.00 | $118.97 Million | -- |
| 2018-12-31 | 11.69% | $13.96 Million | $119.40 Million | +5.46pp |
| 2008-12-31 | 6.23% | $2.05 Million | $32.89 Million | -19.40pp |
| 2007-12-31 | 25.62% | $16.08 Million | $62.74 Million | +23.21pp |
| 2006-12-31 | 2.41% | $829.00K | $34.40 Million | -3.39pp |
| 2005-12-31 | 5.80% | $3.25 Million | $56.01 Million | -1.49pp |
| 2004-12-31 | 7.29% | $2.74 Million | $37.64 Million | -43.28pp |
| 2002-12-31 | 50.57% | $10.65 Million | $21.06 Million | -13.91pp |
| 2001-12-31 | 64.48% | $12.94 Million | $20.07 Million | +5.71pp |
| 2000-12-31 | 58.77% | $11.59 Million | $19.72 Million | +4.79pp |
| 1999-12-31 | 53.97% | $2.50 Million | $4.63 Million | -0.38pp |
| 1998-12-31 | 54.35% | $2.50 Million | $4.60 Million | +11.61pp |
| 1997-12-31 | 42.74% | $5.00 Million | $11.70 Million | -36.21pp |
| 1996-12-31 | 78.95% | $1.50 Million | $1.90 Million | -- |
About Windtree Therapeutics Inc
Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. Its lead product candidate is istaroxime, which is in Phase 2b clinical trials for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. The company also develops AEROSURF, an aerosolized KL4 sur… Read more